Merck Gets $700 Million from Blackstone Life Sciences for Development of Cancer Drug
By Nicholas G. Miller
Blackstone Life Sciences agreed to give Merck $700 million to support its development of an investigational cancer drug called sacituzumab tirumotecan in exchange for low-to-mid-single-digit royalties on the drug.
Merck is currently evaluating the drug in 15 phase three clinical trials spanning six tumor types, including breast, endometrial and lung cancers.
The $700 million will fund a portion of the development costs for the drug expected to be incurred throughout 2026. The agreement makes Blackstone eligible for royalties on net sales of the drug across all approved indications, contingent upon receipt of regulatory approval in the U.S. for first-line treatment of triple-negative-breast cancer.
Merck will retain decision-making authority and control over the development, manufacturing and commercialization of the drug.
Write to Nicholas G. Miller at nicholas.miller@wsj.com.
(END) Dow Jones Newswires
November 04, 2025 07:35 ET (12:35 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
5 Stocks to Sell for Tax-Loss Harvesting
33 Undervalued Stocks to Buy Before the Market Shifts Again
Ask the Analyst: What Is the Best Source for Low-Risk Tax-Free Income?
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States